The Food and Drug Administration (FDA) has finalized a rule expanding the availability of abortion pills. The new rule allows for the distribution of mifepristone, a medication used in combination with misoprostol for medication abortions, through telemedicine. This means that women will be able to consult with a healthcare provider remotely, and the provider can then provide a prescription for the medication via mail or delivery.
The FDA had previously restricted the use of mifepristone to only in-person visits with a healthcare provider and required that it be dispensed in a clinical setting. The new rule removes these restrictions, which will increase access to medication abortion for women, particularly in rural and underserved areas.
“The FDA’s decision to allow for the distribution of mifepristone through telemedicine during the COVID-19 pandemic is a major victory for women’s health,” said Dr. Janet Woodcock, the acting commissioner of the FDA in a statement. “This decision will help ensure that individuals have access to safe, effective and affordable options for ending a pregnancy.”
The new rule also extends the duration during which mifepristone can be used for medication abortion from 49 days of pregnancy to 70 days, aligning with the World Health Organization (WHO) guidelines.
This move is being seen as a significant step in increasing access to safe and effective abortion care, particularly during the ongoing COVID-19 pandemic. Telemedicine has become an increasingly important tool in providing healthcare during the pandemic, and this new rule allows for the use of telemedicine in accessing medication abortion.
The decision has been met with mixed reactions, with pro-choice groups welcoming the move as a step towards increasing access to safe and effective abortion care, while pro-life groups have criticized the decision as a threat to women’s health and safety.
In conclusion, The Food and Drug Administration (FDA) has finalized a rule expanding the availability of abortion pills. The new rule allows for the distribution of mifepristone, a medication used in combination with misoprostol for medication abortions, through telemedicine. This means that women will be able to consult with a healthcare provider remotely, and the provider can then provide a prescription for the medication via mail or delivery. The decision has been met with mixed reactions, with pro-choice groups welcoming the move as a step towards increasing access to safe and effective abortion care, while pro-life groups have criticized the decision as a threat to women’s health and safety.
